Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Mechanisms of aberrant regulation of the Met receptor tyrosine kinase in cancer

EF 2023-24

Résumé
Normal functioning of the body requires that all the cells accomplish their function according to a precise and detailed plan. When these normal growth or modulatory signals are altered, this results in an imbalance of signals that promote growth, suppress death, and enhance the invasive capacity of cells contributing to cancer growth and progression. These growth signals are frequently altered in cancer. One of these signals involves a regulator of growth and invasion called the Met receptor. This controls normal tissue organization during development and wound healing. However, when these signals become activated in human solid cancers, such as lung, gastric, kidney, head and neck and hard to treat breast cancers, Met contributes to tumour cell invasion, resistance to therapies and progression to metastases. We now know that alterations in the Met receptor, involving a new and poorly understood variant called delta exon 14, occur as a mechanism of resistance to precision therapies currently in the clinic for many of these cancers. Increasing evidence supports the use of Met-targeting therapies in cancers that harbor molecular alterations in Met but we also need to identify patients who will respond to such therapies as well as those who will develop alterations in Met as a mechanism of resistance to other therapies currently in the clinic. My goal is to develop new mechanistic understanding on how Met promotes aggressive and therapy resistant cancers.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
506369
Name
Pecora Isabella H
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Mechanisms of aberrant regulation of the Met receptor tyrosine kinase in cancer
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Models; Cell Cycle; Cell Signalling; Invasion; Lung Cancer; Mechanism Of Activation; Negative Feedback; Phosphorylation; Receptor Tyrosine Kinase; Structure Function
Abstract
Normal functioning of the body requires that all the cells accomplish their function according to a precise and detailed plan. When these normal growth or modulatory signals are altered, this results in an imbalance of signals that promote growth, suppress death, and enhance the invasive capacity of cells contributing to cancer growth and progression. These growth signals are frequently altered in cancer. One of these signals involves a regulator of growth and invasion called the Met receptor. This controls normal tissue organization during development and wound healing. However, when these signals become activated in human solid cancers, such as lung, gastric, kidney, head and neck and hard to treat breast cancers, Met contributes to tumour cell invasion, resistance to therapies and progression to metastases. We now know that alterations in the Met receptor, involving a new and poorly understood variant called delta exon 14, occur as a mechanism of resistance to precision therapies currently in the clinic for many of these cancers. Increasing evidence supports the use of Met-targeting therapies in cancers that harbor molecular alterations in Met but we also need to identify patients who will respond to such therapies as well as those who will develop alterations in Met as a mechanism of resistance to other therapies currently in the clinic. My goal is to develop new mechanistic understanding on how Met promotes aggressive and therapy resistant cancers.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pecora, Isabella H
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~